Apixaban or Vitamin K Antagonists for Stroke Prevention in Patients With Atrial Fibrillation on Hemodialysis: Results of the Randomized Axadia-AFNET 8 Trial

被引：0
|
作者：
Reinecke, Holger [1 ]
Bauersachs, Rupert [2 ]
Breithardt, Gunter [3 ]
Engelbertz, Christiane [3 ]
Gerss, Joachim [4 ]
Gaerlich, Dennis [4 ]
Juergensmeyer, Sabine [5 ]
Wanner, Christoph [6 ]
Kirchhof, Paulus [7 ]
机构：
[1] Univ Hosp Muenster, Dept Cardiol, Munster, Germany
[2] Agaples Bethanien Hosp, Med Care Cntr, Frankfurt, Germany
[3] Univ Hosp Muenster, Dept Cardiol, Munster, Germany
[4] Univ Munster, Inst Biostat & Clin Rsch, Munster, Germany
[5] Atrial Fibrillat Network, Munster, Germany
[6] Univ Hosp, Div Nephrol, Dept Med, Wurzburg, Germany
[7] Univ Hosp Hamburg Eppendorf, Dept Cardiol, Hamburg, Germany
来源：
CIRCULATION | 2022年 / 146卷 / 25期
关键词：
atrialfibrillation; apixaban; vitamin K antagonist; hemodialysis; randomized; controlled trial; stroke prevention;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
18519
引用
收藏
页码：E589 / E590
页数：2
相关论文
共 50 条
  • [21] Meta-analysis of efficacy and safety of apixaban and uninterrupted apixaban therapy compared to vitamin K antagonists in patients undergoing catheter ablation for atrial fibrillation
    Ukaigwe, Anene
    Shrestha, Pragya
    Karmacharya, Paras
    Hussain, Sarah K.
    Samii, Soraya
    Gonzalez, Mario D.
    Wolbrette, Deborah
    Naccarrelli, Gerald V.
    JOURNAL OF INTERVENTIONAL CARDIAC ELECTROPHYSIOLOGY, 2017, 48 (02) : 223 - 233
  • [22] Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation on chronic hemodialysis: a meta-analysis of randomized controlled trials
    Denilsa D. P. Navalha
    Nicole Felix
    Alleh Nogueira
    Mariana Clemente
    Alice D. Marinho
    Rafael Oliva Morgado Ferreira
    Eric Pasqualotto
    Caroline Serafim Dagostin
    Luis Cláudio Santos Pinto
    Gilson C. Fernandes
    International Urology and Nephrology, 2024, 56 : 2001 - 2010
  • [23] Bleeding During Treatment With Aspirin Versus Apixaban in Patients With Atrial Fibrillation Unsuitable for Warfarin The Apixaban Versus Acetylsalicylic Acid to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin k Antagonist Treatment (AVERROES) Trial
    Flaker, Greg C.
    Eikelboom, John W.
    Shestakovska, Olga
    Connolly, Stuart J.
    Kaatz, Scott
    Budaj, Andrzej
    Husted, Steen
    Yusuf, Salim
    Lip, Gregory Y. H.
    Hart, Robert G.
    STROKE, 2012, 43 (12) : 3291 - +
  • [24] Use of vitamin K antagonists for secondary stroke prevention depends on the treating healthcare provider in Germany – results from the German AFNET registry
    Karl Georg Haeusler
    Andrea Gerth
    Tobias Limbourg
    Ulrich Tebbe
    Michael Oeff
    Karl Wegscheider
    András Treszl
    Ursula Ravens
    Thomas Meinertz
    Paulus Kirchhof
    Günter Breithardt
    Gerhard Steinbeck
    Michael Nabauer
    BMC Neurology, 15
  • [25] Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation
    Zirlik, Andreas
    Bode, Christoph
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2017, 43 (03) : 365 - 379
  • [26] Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: A French payer perspective
    Chevalier, Julie
    Delaitre, Olivier
    Hammes, Florence
    de Pouvourville, Gerard
    ARCHIVES OF CARDIOVASCULAR DISEASES, 2014, 107 (6-7) : 381 - 390
  • [27] Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial
    Rao, Meena P.
    Halvorsen, Sigrun
    Wojdyla, Daniel
    Thomas, Laine
    Alexander, John H.
    Hylek, Elaine M.
    Hanna, Michael
    Cecilia Bahit, M.
    Lopes, Renato D.
    De Caterina, Raffaele
    Erol, Cetin
    Goto, Shinya
    Lanas, Fernando
    Lewis, Basil S.
    Husted, Steen
    Gersh, Bernard J.
    Wallentin, Lars
    Granger, Christopher B.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2015, 4 (12):
  • [28] Vitamin K Antagonists and Direct Oral Anticoagulants in Nonagenarian Patients With Atrial Fibrillation
    Raposeiras-Roubin, Sergio
    Alonso Rodriguez, David
    Camacho Freire, Santiago Jesus
    Abu-Assi, Emad
    Cobas-Paz, Rafael
    Rodriguez Pascual, Carlos
    Garcia Comesana, Julio
    Gonzalez-Carrero Lopez, Alberto
    Cubelos Fernandez, Naiara
    Lopez-Masjuan Rios, Alvaro
    Cespon-Fernandez, Maria
    Munoz-Pousa, Isabel
    Caneiro-Queija, Berenice
    Rodriguez Albarran, Adrian
    Alvarez Castanera, Sara
    Verisimo Guillen, Julia
    Carpintero Vara, Alberto
    Barreiro Pardal, Cristina
    Dominguez-Erquicia, Pablo
    Manuel Dominguez-Rodriguez, Luis
    Diaz Fernandez, Jose Francisco
    Fernandez Vazquez, Felipe
    Iniguez-Romo, Andres
    JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION, 2020, 21 (03) : 367 - +
  • [29] Major bleeding in patients with atrial fibrillation receiving vitamin K antagonists: a systematic review of randomized and observational studies
    Roskell, Neil S.
    Samuel, Miny
    Noack, Herbert
    Monz, Brigitta U.
    EUROPACE, 2013, 15 (06): : 787 - 797
  • [30] Patient characteristics and stroke and bleeding events in nonvalvular atrial fibrillation patients treated with apixaban and vitamin K antagonists: a Spanish real-world study
    Ramagopalan, Sreeram, V
    Sicras-Mainar, Antoni
    Polanco-Sanchez, Carlos
    Carroll, Robert
    de Bobadilla, Jaime F.
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2019, 8 (14) : 1201 - 1212
12345